KETAMINE
CO-CHAIRS
Robert Meisner, MD | McLean Hospital
Mark Niciu, MD, PhD | University of Iowa
WHY A TASK GROUP?
In November 2019, the NNDC approved the creation of a working group on racemic ketamine and bioactive ketamine metabolites, including esketamine. The purpose of the NNDC Ketamine Task Group has been to address the emerging need to share information and learn from each other’s experiences as ketamine and esketamine clinics are established across the Network. Ketamine and esketamine both are addressed within this group; subgroups may be formed, as appropriate. Early on, the group has been learning from each other as these clinics come online, by facilitating communication of experiences and solutions to common challenges.
CURRENT PROJECTS
- Continuous knowledge sharing
- Position statement: addressing support for reimbursement from insurance companies regarding IV ketamine
- Harmonization of Epic and REMS data recording/reporting
PAST ACCOMPLISHMENTS
- 2020 survey of NNDC member sites addressing research & clinical practice, administration logistics & operations, and COVID-19 impacts
MORE INFORMATION
For more information about this task group, please contact Program Manager Mary Laffey ([email protected]).
Each year, NNDC Task Groups are invited to apply for NNDC Momentum Grants to fund pilot projects that can be used to generate proposals for larger federal or foundation grants. For details, visit the NNDC Momentum Grants page.
page updated: 02/2023